ASCO 2022
June 2022. Key Updates from ASCO 2022 1. Immunotherapy treatment results in an “unprecedented” clinical complete response in 100% of first 14 patients with rectal cancer In a study of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, 6 months of treatment with the immunotherapy agent dostar...
CONTINUE READING
HER2 Therapies for Patients with mCRC
May 2022. Image source: https://www.whathealth.com/breastcancer/her2receptor.html HER2 (human epidermal growth factor receptor 2) is a protein receptor found in all human cells and is responsible for controlling cell growth and repair. When the HER2 gene acquires mutations which cause it to be amplified or overexpressed in t...
CONTINUE READING
Overall survival associated with Pembrolizumab (Keytruda) vs. Chemotherapy in MSI-H/dMMR mCRC
May 2022 The KEYNOTE-177 trial is a landmark study in colorectal cancer treatment that evaluated the efficacy and safety of the immunotherapy drug, pembrolizumab (Keytruda), compared to standard of care chemotherapy for patients with microsatellite instability high (MSI-H), mismatch repair deficient (dMMR) metastatic colo...
CONTINUE READING
Alcohol intake and risk of alcohol-related cancer
April 2022. A new study from Australia found that heavy drinking in early adulthood may increase the risk for alcohol-related cancers, including colorectal cancer (CRC), even after drinking decreases or stops entirely in middle age. Alcohol is a known risk factor for CRC – the 2018 World Cancer Research Fund and Americ...
CONTINUE READING
Associations between unprocessed red meat and processed meat with risk of recurrence and mortality in patients with stage III colon cancer
April 2022. A study published in JAMA Network Open investigated whether consumption of unprocessed red meat or processed meats such as bacon, ham, or smoked meats after a colon cancer diagnosis were associated with a higher risk of recurrence and death. Both the American Cancer Society and the American Institute for Cance...
CONTINUE READING
